Go Pro
NASDAQ:BRTX

Biorestorative Therapies Q4 2025 Earnings Report

Biorestorative Therapies logo
$2.51 -0.09 (-3.46%)
Closing price 09/24/2026 03:59 PM Eastern
Extended Trading
$2.49 -0.02 (-0.72%)
As of 09/24/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
-$7.40
Consensus EPS
-$7.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.15 million
Beat/Miss
Missed by -$130.40 thousand
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, March 26, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Biorestorative Therapies' Q2 2026 earnings is estimated for Tuesday, September 29, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Biorestorative Therapies Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
BioRestorative Therapies Announces Reverse Stock Split
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health.

Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc. BioRestorative has advanced BRTX-100 through clinical development and has evaluated its safety and potential effectiveness in patients with chronic lower-back pain.

The company is also developing ThermoStem, a cell therapy platform intended to generate brown adipose tissue for potential applications involving obesity and metabolic disorders. BioRestorative Therapies is based in the United States and conducts its development activities through research, clinical and regulatory programs. The company’s candidates remain subject to clinical testing and regulatory review, and their eventual availability and indications are not assured.

View Biorestorative Therapies Profile